Fasiglifam 25 mg BID vs 50 mg QD

Summary

To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.

Timeline

Start

2013-10

Primary completion

2014-01

Completion

2014-01

Drugs

Indications